Wealth Management Associates Inc. Buys 5,053 Shares of Pfizer Inc. $PFE

Wealth Management Associates Inc. boosted its stake in shares of Pfizer Inc. (NYSE:PFE) by 10.2% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 54,720 shares of the biopharmaceutical company’s stock after buying an additional 5,053 shares during the period. Wealth Management Associates Inc.’s holdings in Pfizer were worth $1,387,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of the business. William B. Walkup & Associates Inc. increased its holdings in shares of Pfizer by 1.2% in the 4th quarter. William B. Walkup & Associates Inc. now owns 39,368 shares of the biopharmaceutical company’s stock worth $1,044,000 after purchasing an additional 454 shares in the last quarter. Members Trust Co increased its holdings in shares of Pfizer by 2.1% in the 1st quarter. Members Trust Co now owns 23,175 shares of the biopharmaceutical company’s stock worth $587,000 after purchasing an additional 467 shares in the last quarter. Sutton Place Investors LLC increased its holdings in shares of Pfizer by 5.6% in the 1st quarter. Sutton Place Investors LLC now owns 8,833 shares of the biopharmaceutical company’s stock worth $224,000 after purchasing an additional 472 shares in the last quarter. MSH Capital Advisors LLC increased its holdings in shares of Pfizer by 1.4% in the 1st quarter. MSH Capital Advisors LLC now owns 34,585 shares of the biopharmaceutical company’s stock worth $876,000 after purchasing an additional 485 shares in the last quarter. Finally, Signature Estate & Investment Advisors LLC increased its holdings in shares of Pfizer by 2.6% in the 1st quarter. Signature Estate & Investment Advisors LLC now owns 19,254 shares of the biopharmaceutical company’s stock worth $488,000 after purchasing an additional 486 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

A number of research firms have commented on PFE. Citigroup lifted their target price on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. Berenberg Bank reduced their target price on Pfizer from $28.00 to $25.00 and set a “hold” rating for the company in a report on Thursday, May 29th. HSBC reduced their target price on Pfizer from $27.00 to $26.00 and set a “buy” rating for the company in a report on Monday, May 19th. Jefferies Financial Group raised their price target on Pfizer from $32.00 to $33.00 and gave the stock a “buy” rating in a research note on Wednesday, May 21st. Finally, Morgan Stanley raised their price target on Pfizer from $32.00 to $33.00 and gave the stock an “equal weight” rating in a research note on Wednesday, August 6th. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $28.12.

Pfizer Stock Performance

PFE stock opened at $24.59 on Thursday. The company has a market cap of $139.79 billion, a P/E ratio of 13.08, a price-to-earnings-growth ratio of 0.88 and a beta of 0.55. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $30.43. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The stock’s fifty day moving average price is $24.83 and its 200-day moving average price is $24.33.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.58 by $0.20. The company had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.Pfizer’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period in the previous year, the business earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, equities analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 2nd. Investors of record on Friday, July 25th were given a dividend of $0.43 per share. The ex-dividend date was Friday, July 25th. This represents a $1.72 annualized dividend and a yield of 7.0%. Pfizer’s payout ratio is 91.49%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.